Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Juno Therapeutics

Explore full profile

Is a clinical-stage company, develops immunotherapies for the treatment of cancer

Seattle, United StatesFounded 2013Biotech & Life Sciences
Valuation $9.00B Market cap · 2026
Revenue $112M Latest reported FY

At a glance

Status
Listed
Founded
2013
Headquarters
Seattle, United States
Listing
IPO 2014
Sector
Biotech & Life Sciences
Power Law
Unicorn$1–10B valuation tierThoroughbred$100M+ revenue

Knowledge graph

News, research, reports and resources connected to this company by Dealroom

Investors

4 investors on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Series A4 investors entered at this stage

Talent

Book a demo to see the people
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia 12 alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Alumni founders

5 of 12 startups shown

Former Juno Therapeutics employees who went on to found companies, sorted by Dealroom signal score.

Xaira TherapeuticsEst. 2023
Marc Tessier-LavigneUnited States
Signal score92
Umoja BiopharmaEst. 2019
RCRyan CrismanUnited States
Signal score88
Day One BiopharmaceuticalsEst. 2018
SBSamuel BlackmanUnited States
Signal score83
Sift BiosciencesEst. 2024
Maddie WilliamsUnited States
Signal score81
OnQuality PharmaceuticalsEst. 2018
HONG TANG, MD, FACPChina
Signal score67
7 more alumni-founded companies in this previewBook a demo

Global footprint

Workforce and web traffic by country
Workforce by country
4 countries with
team presence
🇺🇸 United States95.2%
🇨🇭 Switzerland1.6%
🇩🇪 Germany1.6%
🇦🇺 Australia1.6%
4 countries shown
Web traffic by country
710 monthly visits
across markets
🇺🇸 United States98.6%
Top 1 markets shown

Patents

Estimated portfolio value
$307M

174 active patent families included in this estimate.

A patent family groups patent filings for the same invention. Source: Dealroom · PatSnap.

Explore the patent portfolioPatent records, technology areas and peer comparisonsBook a demo

Investments and acquisitions

Disclosed deals where Juno Therapeutics was the backer or acquirer, 2015–2020. Toggle between venture rounds, M&A, or both. The map below is grouped by the target company's sector — the colored pill on each chip is the round type.

Portfolio analysis

6 deals across Juno Therapeutics's capital deployment.

Where the deals concentrate by sector, stage, and decade.

By sectorCount
    By stageCount
      By periodCount

        Where Juno Therapeutics deploys vs peers

        Each axis is a Dealroom topic tag — picked from the cluster's most-tagged themes. Values are normalized per axis: the peer with the highest tag-coverage on that axis sits at the edge, others scale relative to them. Toggle between M&A, venture, or both.

        Compare against

        Juno Therapeutics's portfolio, mapped.

        Stage
        Period
        6 of 6 deals

        Market sentiment

        Posts on X, past 7 days

        An AI-synthesised read of the highest-engagement posts about Juno Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

        Reading the room on X — pulling top posts and synthesizing themes…

        Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

        See Juno Therapeutics on the full Dealroom platform

        Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.

        Book a demo Explore company profiles